← Eichor
Condition: Dystrophia Myotonica 1 Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Dystrophia Myotonica 1

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Personalized Training for People With Rare Neuromuscular Disorders
NA · 5 location(s) · Oslo University Hospital · NCT06708468Establishing Biomarkers and Clinical Endpoints in Myotonic Dystrophy Type 1 (END-DM1) Extension
Phase N/A · 1 location(s) · Virginia Commonwealth University · NCT07700225Remote Assessments and Genetic Determinants of Myotonic Dystrophy
Phase N/A · 1 location(s) · University of Rochester · NCT07505342The United Kingdom National Registry for Myotonic Dystrophy
Phase N/A · 1 location(s) · Newcastle University · NCT04003363Pelvic Floor Muscle Training for Women with Myotonic Dystrophy
NA · 1 location(s) · Université de Sherbrooke · NCT06316778Safety, Tolerability, Pharmacodynamic, Efficacy, and Pharmacokinetic Study of DYNE-101 in Participants With Myotonic Dys
Phase 1/Phase 2 · 20 location(s) · Dyne Therapeutics · NCT05481879The Efficacy and Safety of Once Daily Mexiletine PR in Patients With Myotonic Dystrophy Type 1 and Type 2
Phase 3 · 7 location(s) · Lupin Ltd. · NCT06523400An Open-Label Extension Study of PGN-EDODM1 in People With Myotonic Dystrophy Type 1 (FREEDOM-OLE)
Phase 2 · 3 location(s) · PepGen Inc · NCT07220603Efficacy, Safety, and Tolerability of Zeleciment Basivarsen (DYNE-101) in Participants With Myotonic Dystrophy Type 1
Phase 3 · 21 location(s) · Dyne Therapeutics · NCT07486934Estab Biomarkers and Clinical Endpoints in Myotonic Dystrophy Type 1 (END-DM1)
Phase N/A · 17 location(s) · Virginia Commonwealth University · NCT03981575Assessments in Patients With Muscular Pathology and in Control Subjects : The ActiLiège Next Study
NA · 8 location(s) · Centre Hospitalier Universitaire de Liege · NCT05982119Characterization of Patients With Cardiomyopathy to Identify Critical Patients Candidates for Cardiac Transplantation
Phase N/A · 3 location(s) · IRCCS Azienda Ospedaliero-Universitaria di Bologna · NCT06813443A Clinical Study of PGN-EDODM1 in People With Myotonic Dystrophy Type 1
Phase 2 · 8 location(s) · PepGen Inc · NCT06667453Study of ARO-DM1 in Subjects With Type 1 Myotonic Dystrophy
Phase 1/Phase 2 · 11 location(s) · Arrowhead Pharmaceuticals · NCT06138743Evaluation of the Role of miR-1 in the Pathogenesis and as a Biomarker in Muscular Dystrophies and Congenital Myopathies
NA · 1 location(s) · University Hospital, Clermont-Ferrand · NCT07415837Remote Assessments and Genetic Determinants of Congenital and Childhood Myotonic Dystrophy
Phase N/A · 1 location(s) · University of Rochester · NCT07630389Myotonic Dystrophy and Facioscapulohumeral Muscular Dystrophy Registry
Phase N/A · 1 location(s) · University of Rochester · NCT00082108Myotonic Dystrophy Family Registry
Phase N/A · 1 location(s) · Myotonic Dystrophy Foundation · NCT02398786Study of ATX-01 in Participants With DM1
Phase 1/Phase 2 · 12 location(s) · ARTHEx Biotech S.L. · NCT06300307Safety and Efficacy of Tideglusib in Congenital or Childhood Onset Myotonic Dystrophy
Phase 2/Phase 3 · 14 location(s) · AMO Pharma Limited · NCT05004129A Study to Investigate the Safety, Tolerability, and Efficacy of SAR446268, an Adeno-associated Viral Vector-mediated Ge
Phase 1/Phase 2 · 9 location(s) · Sanofi · NCT06844214Cerebrospinal Fluid Biomarkers of Myotonic Dystrophy
Phase N/A · 1 location(s) · Massachusetts General Hospital · NCT06075693Evaluation of the Efficacy and Safety of Metformin in the Myotonic Dystrophy Type 1 (Steinert's Disease)
Phase 3 · 1 location(s) · Assistance Publique - Hôpitaux de Paris · NCT05532813Development of Quantitative Muscle Imaging as a Biomarker of Disease Endpoints in Myotonic Dystrophy
Phase N/A · 1 location(s) · Wake Forest University Health Sciences · NCT07362875A Phase 1/2 Study of VX-670 in Adult Participants With Myotonic Dystrophy 1 (DM1)
Phase 1/Phase 2 · 26 location(s) · Vertex Pharmaceuticals Incorporated · NCT06185764The Spanish National Registry for Myotonic Dystrophy Type 1
Phase N/A · 8 location(s) · Fundació Institut Germans Trias i Pujol · NCT07385443Gait Analysis Parameter and Upper Limb Evaluation in Adult Patients With Neurological or Metabolic Pathology
NA · 1 location(s) · Centre Hospitalier Universitaire de Liege · NCT07136844
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.